Roche Holding AG’s Alecensa halted the spread of lung cancer for a median of 15 months longer than treatment with rival Pfizer Inc.’s Xalkori with fewer side effects, according to trial results.
A targeted drug being developed by Pfizer Inc. held advanced lung cancer in check longer than AstraZeneca’s Iressa in newly diagnosed patients, but with a higher rate of side effects, according to data.
Merck KGaA struck a deal worth up to €1 billion to acquire five bispecific immuno-oncology antibodies from F-star Alpha.
Investors Sigh With Relief as bluebird bio, Celgene’s CAR-T Candidate Keeps Multiple Myeloma Patients Relapse Free
Although a lot of attention went to unexpected data by China’s Nanjing Legend Biotech, bluebird bio and Celgene had CAR-T data of their own to brag about.
Loxo Oncology Seeks FDA Approval After Breakthrough Drug Larotrectinib Helped Almost Everyone Who Took It
Shares of Loxo Oncology rocketed up more than 48 percent after the company unveiled data from three trials that showed treatment with larotrectinib helped nearly three-quarters of patients battling a variety of cancers.
Women with advanced breast cancer who carry specific genetic mutations experienced double the response rate and delayed disease progression when treated with AstraZeneca’s Lynparza versus standard chemotherapy, according to a late-stage trial.
Pfizer defeated an effort to revive 300+ lawsuits alleging that its antidepressant Zoloft causes cardiac birth defects in children when taken by women during early pregnancy.
A growing number of U.S. states, counties and cities are filing lawsuits accusing drug companies of deceptively marketing opioid painkillers to downplay their addictiveness, but some lawyers say the industry’s highly regulated nature could pose a hurdle to their success.
Endocyte announced the cutting of 40 percent of its workforce as the company recalibrates two clinical programs, EC1169 and EC1456.
Elated Bristol-Myers Squibb, Seattle Genetics Rewrite Agreement to Push Promising Drug Combo Into Phase III
Six months after touting positive data from a Phase I/II combination study of Opdivo and Adcetris in patients with relapsed or refractory classical Hodgkin lymphoma at the American Society of Hematology, Bristol-Myers Squibb and Seattle Genetics are plowing forward into a Phase III trial.
Nearly nine months after slashing 25 percent of the company’s workforce, Iroko Pharmaceuticals is terminating more than 100 full-time and part-time employees.
ViiV Healthcare made regulatory submissions to the EMA and the U.S. FDA for a single-tablet, two-drug regimen of dolutegravir (ViiV Healthcare) and rilpivirine (Janssen).
While data help manufacturers fix plant-floor problems and trace quality issues to their source, it also can prevent recalls. Why not proactively use data to attain an end-to-end view of operations so that product quality can be ensured while reducing recalls?
Dutch healthcare technology company Philips said Thursday it had reached deals with New York’s Memorial Sloan Kettering Cancer Center (MSK) and Utah-based Intermountain Healthcare for them to use its genomics platform for cancer research and treatment.
Roche announces FDA approval of companion diagnostic to identify ALK-positive non-small cell lung cancer patients
Roche announced U.S. FDA approval of the Ventana ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer (NSCLC) patients eligible for treatment with the Novartis drug Zykadia (ceritinib). The Ventana ALK (D5F3) Assay is the only immunohistochemistry (IHC) test approved by the FDA as a companion diagnostic for Zykadia.
Biogen Inc.’s Spinraza secured European Union approval to treat spinal muscular atrophy (SMA), a leading genetic cause of death in infants.
Things are looking bright for tiny startup biotech Cellanyx as the company has made headway on revolutionizing precision diagnostic test for prostate cancer.
The European Commission granted marketing authorization for BioMarin Pharmaceutical’s Brineura for the treatment of tripeptidyl peptidase 1 (TPP1) deficiency.
Jon Ogg, writing for 24/7 Wall Street, looks at seven biopharma stocks that have the potential to double or more in value during 2017.
The white paper explores trends and market forces affecting organized provider groups (OPGs) and identifies opportunities for pharmaceutical manufacturers to partner with OPGs to develop mutually beneficial programs addressing areas of shared interest.